ARR-002
Solid Tumors
DiscoveryNovel dual-target MUC16/NaPi2b tetravalent ADC from Aarvik partnership
Key Facts
Indication
Solid Tumors
Phase
Discovery
Status
Novel dual-target MUC16/NaPi2b tetravalent ADC from Aarvik partnership
Company
About ArriVent Biopharma
Founded in 2021, ArriVent Biopharma identifies and in-licenses promising drug candidates from global innovation hubs, particularly China, to develop them for worldwide markets. The company's mission is to ensure differentiated medicines for difficult-to-treat cancers reach global patient populations. Led by a team with a proven track record in drug development and approvals, ArriVent's strategy leverages deep oncology expertise and regulatory experience to maximize the potential of its pipeline.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| GSK4362676 | GSK plc | Phase 1 |
| ABBV-154 | AbbVie | Phase 1 |
| TAK-981 | Takeda Pharmaceutical | Phase 1/2 |
| TAK-676 | Takeda Pharmaceutical | Phase 1 |
| TAK-573 | Takeda Pharmaceutical | Phase 1 |
| TAK-164 | Takeda Pharmaceutical | Phase 1 |
| SHR-1316 | Jiangsu Hengrui Medicine | Phase 1/2 |
| BAY 2927088 | Bayer | Phase 1 |
| ASP1929 | Astellas Pharma | Phase 2 |
| IBI188 | Innovent Biologics | Phase 1 |
| Bispecific Antibody | Akeso | Phase 1/2 |
| CSPC-DM02 | CSPC Pharmaceutical Group Limited | Phase 2 |